BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 8165852)

  • 1. Study of pertussis vaccines in infants: comparison of response to acellular pertussis DTP vaccines containing 25 micrograms of FHA and either 25 or 8 micrograms of PT with response to whole-cell pertussis DTP vaccine.
    Vanura H; Just M; Ambrosch F; Berger RM; Bogaerts H; Wynen J; Vandevoorde D; Wiedermann G
    Vaccine; 1994; 12(3):210-4. PubMed ID: 8165852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acellular pertussis diphtheria-tetanus-pertussis vaccine containing separately purified pertussis toxoid, filamentous haemagglutinin and 69 kDa outer membrane protein as a booster in children.
    Kanra G; Ceyhan M; Vandevoorde D; Bogaerts H
    Eur J Pediatr; 1993 Jun; 152(6):478-83. PubMed ID: 8335014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-response to a two-component acellular pertussis vaccine in infants and comparison with whole-cell vaccine.
    Auerbach BS; Lake AM; Wilson ME; Willingham FF; Shematek J; Moulton L; Deforest A; Halsey NA
    Biologicals; 1998 Jun; 26(2):145-53. PubMed ID: 9811522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized controlled trial of acellular diphtheria, pertussis and tetanus vaccines in southern Ghana.
    Afari EA; Kamiya Y; Nkrumah FK; Dunyo SK; Akpedonu P; Kamiya H; Fukai F
    Ann Trop Paediatr; 1996 Mar; 16(1):39-48. PubMed ID: 8787364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of two acellular pertussis vaccines with different pertussis toxoid and filamentous hemagglutinin content in infants 2-6 months old.
    Halperin SA; Eastwood B; Barreto L; Mills E; Blatter M; Reisinger K; Bader G; Keyserling H; Roberts EA; Guasparini R
    Scand J Infect Dis; 1995; 27(3):279-87. PubMed ID: 8539554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative safety and immunogenicity of an acellular versus whole-cell pertussis component of diphtheria-tetanus-pertussis vaccines in Senegalese infants.
    Simondon F; Yam A; Gagnepain JY; Wassilak S; Danve B; Cadoz M
    Eur J Clin Microbiol Infect Dis; 1996 Dec; 15(12):927-32. PubMed ID: 9031875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-response to acellular pertussis vaccine and comparison with whole cell pertussis vaccine at 15-24 months and 4-6 years of age. Acellular Pertussis Vaccine Study Team.
    Auerbach BS; Wilson ME; Lake AM; Deforest A; Steinhoff M; Halsey NA
    Vaccine; 1992; 10(1):14-20. PubMed ID: 1539456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acellular vaccines induce cell-mediated immunity to Bordetella pertussis antigens in infants undergoing primary vaccination against pertussis.
    Ausiello CM; Urbani F; La Sala A; Lande R; Piscitelli A; Cassone A
    Dev Biol Stand; 1997; 89():315-20. PubMed ID: 9272365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody response and reactions to completion of a four-dose series with a two- or three-component acellular pertussis vaccine compared to whole cell pertussis vaccine.
    Pichichero ME; Green JL; Francis AB; Marsocci SM; Murphy AM; Buscarino C
    Scand J Infect Dis; 1996; 28(2):159-63. PubMed ID: 8792483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.
    Salmaso S; Mastrantonio P; Tozzi AE; Stefanelli P; Anemona A; Ciofi degli Atti ML; Giammanco A;
    Pediatrics; 2001 Nov; 108(5):E81. PubMed ID: 11694665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses.
    Cherry JD; Gornbein J; Heininger U; Stehr K
    Vaccine; 1998 Dec; 16(20):1901-6. PubMed ID: 9796041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of combined diphtheria-tetanus-pertussis (whole cell and acellular)-Haemophilus influenzae-b conjugate vaccines administered to Indonesian children.
    Richie E; Punjabi NH; Harjanto SJ; Wangsasaputral F; Sukandar M; Supriatman M; Simanjuntak CH; Que JU; Cryz SJ
    Vaccine; 1999 Mar; 17(11-12):1384-93. PubMed ID: 10195774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age.
    Silfverdal SA; Assudani D; Kuriyakose S; Van Der Meeren O
    Hum Vaccin Immunother; 2014; 10(10):2795-8. PubMed ID: 25483640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An evaluation of the safety and immunogenicity of a five-component acellular pertussis, diphtheria, and tetanus toxoid vaccine (DTaP) when combined with a Haemophilus influenzae type b-tetanus toxoid conjugate vaccine (PRP-T) in Taiwanese infants.
    Lee CY; Thipphawong J; Huang LM; Lee PI; Chiu HH; Lin W; Debois H; Harrison D; Xie F; Barreto L
    Pediatrics; 1999 Jan; 103(1):25-30. PubMed ID: 9917435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two trials of an acellular DTP vaccine in comparison with a whole-cell DTP vaccine in infants: evaluation of two PT doses and two vaccination schedules.
    Just M; Kanra G; Bogaerts H; Berger R; Ceyhan M; Pêtre J
    Dev Biol Stand; 1991; 73():275-83. PubMed ID: 1778319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomised controlled trial with a diphtheria-tetanus-acellular pertussis (dTpa) vaccine in adults.
    Van der Wielen M; Van Damme P; Joossens E; François G; Meurice F; Ramalho A
    Vaccine; 2000 Apr; 18(20):2075-82. PubMed ID: 10715521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum IgG antibody responses to pertussis toxin and filamentous hemagglutinin in nonvaccinated and vaccinated children and adults with pertussis.
    Trollfors B; Taranger J; Lagergård T; Sundh V; Bryla DA; Schneerson R; Robbins JB
    Clin Infect Dis; 1999 Mar; 28(3):552-9. PubMed ID: 10194077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reactogenicity and immunogenicity of a three-component acellular pertussis vaccine administered as the primary series to 2, 4 and 6 month old infants in the United States.
    Bernstein HH; Rothstein EP; Pichichero ME; Green JL; Reisinger KS; Blatter MM; Halpern J; Arbeter AM; Bernstein DI; Smith V
    Vaccine; 1995 Dec; 13(17):1631-5. PubMed ID: 8719512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative study of Lederle/Takeda acellular and Lederle whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants in Germany.
    Heininger U; Cherry JD; Christenson PD; Eckhardt T; Göering U; Jakob P; Kasper W; Schweingel D; Laussucq S; Hackell JG
    Vaccine; 1994 Jan; 12(1):81-6. PubMed ID: 8303945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of 13 acellular pertussis vaccines: overview and serologic response.
    Edwards KM; Meade BD; Decker MD; Reed GF; Rennels MB; Steinhoff MC; Anderson EL; Englund JA; Pichichero ME; Deloria MA
    Pediatrics; 1995 Sep; 96(3 Pt 2):548-57. PubMed ID: 7659475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.